Hims closes its compounded GLP-1 programme to new patients
Following a settlement with Novo Nordisk, one of the largest consumer platforms exits compounded semaglutide.
Hims closed its compounded GLP-1 programme to new patients in March 2026 following a settlement with Novo Nordisk, continuing to offer brand-name products billed separately from membership.
It is part of a pattern rather than an isolated exit: Ro and the WeightWatchers clinic moved toward brand-only models, and Calibrate operates a brand-only membership.
Comparisons written before spring 2026 should be checked programme by programme. Several sites still rank these companies for compounded medication they no longer sell.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement or the clinical review behind a prescription.
Where a development moves a figure we publish, the change is recorded with its date on our methodology page rather than edited in silently.
How to verify this yourself
Regulatory claims should be checked against the agency rather than coverage of the agency. FDA publishes warning letters searchable by company name and a drug shortage database, both free and both more current than any summary.